[12] Patent
[11] Patent No.:GC0007677  
[45] Date of Publishing the Grant of the Patent: 30/Apr /2018                48/2018  
Number of the Decision to Grant the Patent:2018/126655
Date of the Decision to Grant the Patent:30/Apr/2018

[21] Application No.:GC 2012-21413

[22] Filing Date:2/6/2012

[30] Priority:

[33] State [32] Priority date [31] Priority No.


[72] Inventors:1- CHOI, Suk Young،2- KO, Youn Kyung،3- SO, Sin Eon

[73] Owner: LG LIFE SCIENCES LTD, 58, Sinmunno 2-ga, Saemunan-ro, Jongno-gu, 110-062, Seoul, North Korea

[74] Agent: Hassan Al-Mulla




Int. Cl.: A61K 31/198, 38/16, 9/08; A61P 19/02, 37/02 (2006.01)

[56] Cited Documents:

-US 2010-0285011 A1 (T. MORICHIKA et al.) 11 November 2010
-US 2006-0292148 A1 (T. MATSUMOTO) 28 December 2006
-US 7785592 B2 (C. N. OLIVER et al.) 31 August 2010
Examiner: PH. Neda J. AlMuallem

[57] Abstract: The present invention relates to a stable liquid formulation of etanercept (recombinant p75 sTNFR:Fc fusion protein), and more particularly, to a liquid formulation comprising one or more stabilizers selected from the group consisting of methionine, lysine, histidine, and pharmaceutically acceptable salts thereof in an amount sufficient to reduce by-product formation of etanercept during storage. The liquid formulation according to the present invention effectively reduces production of etanercept by-products and to stably maintain its pharmaceutical efficacies for long-term storage. Therefore, the reconstitution procedure is not required before administration, and the sterile formulation can be administered to patients to ensure patient safety. Thus, it can be applied to the fields in need of etanercept treatment.
No. of claims: 15


Note: Any interested individual may, within 3 months of publication of the grant, file objection thereof with the Grievance Committee after payment of grievance fees.